The METHYLOMIC project aims to implement epigenetic blood tests to help physicians determine the most optimal treatment for each Crohn’s disease patient. We will be doing a prospective trial in almost 400 patients.
Prof. dr. Wouter de Jonge and Andrew Yi Lim talked about the progress on this project in a webinar on July 5th, organised by our partner GenDx.
The consortium comprises eighteen participants consisting of clinical, epigenetic, and DNA diagnostics experts, patient organizations, and companies across nine countries to ensure effective communication and commitment to help ease the challenges of patients with Crohn’s disease, Rhematoid Arthritis and Psoriasis.
Attendances of the webinar received 0.15 continuing education credits (CECs).